Fundraising Fox
Impel Neuropharma
Seattle, US · Delaware corporation · 5 known investors
Find your way into Impel Neuropharma
Each arrow is one introduction. Sign up to fill in the first one.
304 people can intro you to John
Ask David Allison to introduce you to John D. Hoekman
You →David · together at Impelpharma →John
Sign up to find every way you can get introduced to Impel Neuropharma
- Your email: who you already know at Impel Neuropharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Impel Neuropharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology. Its first approved product treats acute migraine in adults, and the company pursues partnerships and licensing for small and large molecules.
Founders & leadership
JD
John D. HoekmanFounder
Board
MH
Michael HiteBoard director
SP
Stewart ParkerBoard director
Investors · 5
5AM Ventureslisted by 5AM VenturesSan Francisco · $100K – $4M
How we know: 5AM Ventures's portfolio page · Not right? Tell us
.jpeg){kind=logo}
B Capital GroupinferredSan Francisco · $10M – $50Mvia Robert Mittendorff · board
How we know: board seat on SEC Form D · Not right? Tell us
venBio Global StrategicinferredSan Francisco
How we know: board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$36.2M disclosed across 6 of 12 rounds · 2015–2021
▶$1.9MofferedApr 2021 · 1 investors · Other Health CareRule 506(b)
▶$1.9MofferedApr 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John LeamanExecutive Officer
- Aaron RoystonDirector
- John D. HoekmanExecutive Officer, Director
- Ali SatvatDirector
- Adrian AdamsExecutive Officer, Director
- David AllisonDirector
- Mahendra ShahDirector
- Diane WilfongDirector
- Robert MittendorffDirector
- Tim NelsonDirector
- Stewart ParkerDirector
- Offering amount
- $1.9M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedMar 2021 · 8 investors · Other Health CareRule 506(b)
▶$7.5MraisedMar 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert MittendorffDirector
- Tim NelsonDirector
- Ali SatvatDirector
- John LeamanExecutive Officer
- Diane WilfongDirector
- Adrian AdamsExecutive Officer, Director
- John D. HoekmanExecutive Officer, Director
- Stewart ParkerDirector
- Aaron RoystonDirector
- Mahendra ShahDirector
- David AllisonDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$490KofferedFeb 2021 · 2 investors · Other Health CareRule 506(b)
▶$490KofferedFeb 2021 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John D. HoekmanExecutive Officer, Director
- Stewart ParkerDirector
- Aaron RoystonDirector
- Mahendra ShahDirector
- David AllisonDirector
- Adrian AdamsExecutive Officer, Director
- Tim NelsonDirector
- Ali SatvatDirector
- John LeamanExecutive Officer
- Diane WilfongDirector
- Robert MittendorffDirector
- Offering amount
- $490K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MofferedMay 2020 · 1 investors · Other Health CareRule 506(b)
▶$5.6MofferedMay 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John D. HoekmanExecutive Officer, Director
- Aaron RoystonDirector
- Adrian AdamsExecutive Officer, Director
- Stewart ParkerDirector
- Diane WilfongDirector
- Tim NelsonDirector
- David AllisonDirector
- Ali SatvatDirector
- Mahendra ShahDirector
- Robert MittendorffDirector
- John LeamanExecutive Officer
- Offering amount
- $5.6M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$481.5KofferedJan 2020 · 1 investors · Other Health CareRule 506(b)
▶$481.5KofferedJan 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RoystonDirector
- Adrian AdamsDirector
- Diane WilfongDirector
- John LeamanExecutive Officer
- Ali SatvatDirector
- Tim NelsonDirector
- Robert MittendorffDirector
- Jon CongletonExecutive Officer, Director
- David AllisonDirector
- Mahendra ShahDirector
- Stewart ParkerDirector
- John D. HoekmanExecutive Officer, Director
- Offering amount
- $481.5K
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MofferedJul 2019 · 1 investors · Other Health CareRule 506(b)
▶$1.6MofferedJul 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tim NelsonDirector
- John LeamanExecutive Officer
- Ali SatvatDirector
- Robert MittendorffDirector
- Jon CongletonExecutive Officer, Director
- David AllisonDirector
- Mahendra ShahDirector
- Aaron RoystonDirector
- John D. HoekmanExecutive Officer, Director
- Stewart ParkerDirector
- Offering amount
- $1.6M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MofferedFeb 2019 · 4 investors · Other Health CareRule 506(b)
▶$1.4MofferedFeb 2019 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mahendra ShahDirector
- Stewart ParkerDirector
- Aaron RoystonDirector
- Robert MittendorffDirector
- Ali SatvatDirector
- John D. HoekmanExecutive Officer, Director
- Tim NelsonDirector
- Jon CongletonExecutive Officer, Director
- Jim YoungDirector
- Offering amount
- $1.4M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.3MraisedDec 2016 · 10 investors · Other Health CareRule 506(b)
▶$22.3MraisedDec 2016 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jim YoungDirector
- Stewart ParkerDirector
- Mahendra ShahDirector
- Aaron RoystonDirector
- John D. HoekmanExecutive Officer, Director
- Offering amount
- $37.3M
- Amount sold
- $22.3M
- Sales commissions
- $1M
- Finders' fees
- $2.5K
- Placement agents
- Cascadia Capital, LLC
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $675.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $149.5K |
| Department of DefenseOffice for Chemical and Biological Defense | Phase II | 2011 | $749.6K |
| Department of DefenseOffice for Chemical and Biological Defense | Phase I | 2010 | $98.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $495.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Impel Neuropharma do?
- Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology. Its first approved product treats acute migraine in adults, and the company pursues partnerships and licensing for small and large molecules.
- Who founded Impel Neuropharma?
- Impel Neuropharma was founded by John D. Hoekman.
- Who are Impel Neuropharma's investors?
- Impel Neuropharma's investors include 5AM Ventures, B Capital Group, venBio Global Strategic, venBio Partners, Westlake Village BioPartners.
- How much funding has Impel Neuropharma raised?
- Impel Neuropharma has disclosed $36.2M raised across 6 of its 12 known rounds.
- Where is Impel Neuropharma headquartered?
- Impel Neuropharma is headquartered in Seattle, US.